REFERENCES

1. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet. 2024;403:1027-50.

2. Pipek LZ, Moraes WAF, Nobetani RM, et al. Surgery is associated with better long-term outcomes than pharmacological treatment for obesity: a systematic review and meta-analysis. Sci Rep. 2024;14:9521.

3. Courcoulas AP, Patti ME, Hu B, et al. Long-term outcomes of medical management vs bariatric surgery in type 2 diabetes. JAMA. 2024;331:654-64.

4. Martin M, Beekley A, Kjorstad R, Sebesta J. Socioeconomic disparities in eligibility and access to bariatric surgery: a national population-based analysis. Surg Obes Relat Dis. 2010;6:8-15.

5. Chang SH, Stoll CRT, Song J, Varela JE, Eagon CJ, Colditz GA. The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003-2012. JAMA Surg. 2014;149:275-87.

6. Longitudinal Assessment of Bariatric Surgery (LABS) Consortium; Flum DR, Belle SH, King WC, et al. Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med. 2009;361:445-54.

7. ASGE Bariatric Endoscopy Task Force; Sullivan S, Kumar N, Edmundowicz SA, et al. ASGE position statement on endoscopic bariatric therapies in clinical practice. Gastrointest Endosc. 2015;82:767-72.

8. Imbus JR, Voils CI, Funk LM. Bariatric surgery barriers: a review using Andersen’s Model of Health Services Use. Surg Obes Relat Dis. 2017;14:404-12.

9. Král J, Machytka E, Horká V, et al. Endoscopic treatment of obesity and nutritional aspects of bariatric endoscopy. Nutrients. 2021;13:4268.

10. Jung SH, Yoon JH, Choi HS, et al. Comparative efficacy of bariatric endoscopic procedures in the treatment of morbid obesity: a systematic review and network meta-analysis. Endoscopy. 2020;52:940-54.

11. Abu Dayyeh BK, Rajan E, Gostout CJ. Endoscopic sleeve gastroplasty: a potential endoscopic alternative to surgical sleeve gastrectomy for treatment of obesity. Gastrointest Endosc. 2013;78:530-5.

12. Fayad L, Adam A, Schweitzer M, et al. Endoscopic sleeve gastroplasty versus laparoscopic sleeve gastrectomy: a case-matched study. Gastrointest Endosc. 2019;89:782-8.

13. Vargas EJ, Rizk M, Gomez-Villa J, et al. The effect of endoscopic sleeve gastroplasty on gastric emptying, motility, and hormones: a comparative prospective study. Gut. 2022;72:1073-80.

14. de Moura DTH, de Moura EGH, Thompson CC. Endoscopic sleeve gastroplasty: from whence we came and where we are going. World J Gastrointest Endosc. 2019;11:322-8.

15. Galvao Neto M, Zundel N, Campos JM, et al. Endoluminal greater curvature plication - a case series. 2013. Available from: https://www.sages.org/meetings/annual-meeting/abstracts-archive/endoluminal-greater-curvature-plication-a-case-series/. [Last accessed on 20 Jun 2025].

16. Beran A, Matar R, Jaruvongvanich V, et al. Comparative effectiveness and safety between endoscopic sleeve gastroplasty and laparoscopic sleeve gastrectomy: a meta-analysis of 6775 individuals with obesity. Obes Surg. 2022;32:3504-12.

17. Marincola G, Gallo C, Hassan C, et al. Laparoscopic sleeve gastrectomy versus endoscopic sleeve gastroplasty: a systematic review and meta-analysis. Endosc Int Open. 2021;9:E87-95.

18. Sharaiha RZ, Hajifathalian K, Kumar R, et al. Five-year outcomes of endoscopic sleeve gastroplasty for the treatment of obesity. Clin Gastroenterol Hepatol. 2021;19:1051-7.e2.

19. Storm AC, Abu Dayyeh BK. Endoscopic sleeve gastroplasty for obesity: defining the risk and reward after more than 1600 procedures. Gastrointest Endosc. 2019;89:1139-40.

20. Endobariatric Procedural Reimbursement Guide. 2024 Coding & Payment Quick Reference. Available from: https://www.bostonscientific.com/content/dam/bostonscientific/Reimbursement/Gastroenterology/pdf/endobariatric-procedural-reimbursement-guide.pdf. [Last accessed on 20 Jun 2025]

21. Jirapinyo P, Thompson CC. Endoscopic gastric body plication for the treatment of obesity: technical success and safety of a novel technique (with video). Gastrointest Endosc. 2020;91:1388-94.

22. Reja D, Zhang C, Sarkar A. Endoscopic bariatrics: current therapies and future directions. Transl Gastroenterol Hepatol. 2022;7:21.

23. Miller K, Turró R, Greve JW, Bakker CM, Buchwald JN, Espinós JC. MILEPOST multicenter randomized controlled trial: 12-month weight loss and satiety outcomes after pose^SM vs. medical therapy. Obes Surg. 2017;27:310-22.

24. Alexandre F, Lapergola A, Vannucci M, et al. Endoscopic management of obesity: Impact of endoscopic sleeve gastroplasty on weight loss and co-morbidities at six months and one year. J Visc Surg. 2023;160:S38-46.

25. Singh S, Bazarbashi AN, Khan A, et al. Primary obesity surgery endoluminal (POSE) for the treatment of obesity: a systematic review and meta-analysis. Surg Endosc. 2022;36:252-66.

26. Ker J, Singh SP, Bai Y, Rao J, Lim T, Wang L. Image thresholding improves 3-dimensional convolutional neural network diagnosis of different acute brain hemorrhages on computed tomography scans. Sensors. 2019;19:2167.

27. Espinós JC, Turró R, Moragas G, et al. Gastrointestinal physiological changes and their relationship to weight loss following the POSE procedure. Obes Surg. 2016;26:1081-9.

28. Sullivan S, Swain JM, Woodman G, Antonetti M, De La Cruz-Muñoz N, Jonnalagadda SS, et al. Randomized sham-controlled trial evaluating efficacy and safety of endoscopic gastric plication for primary obesity: the ESSENTIAL trial. Obesity. 2017;25:294-301.

29. Lopez-Nava G, Asokkumar R, Turró Arau R, Neto MG, Dayyeh BA. Modified primary obesity surgery endoluminal (POSE-2) procedure for the treatment of obesity. VideoGIE. 2020;5:91-3.

30. Lopez Nava G, Arau RT, Asokkumar R, et al. Prospective multicenter study of the primary obesity surgery endoluminal (POSE 2.0) procedure for treatment of obesity. Clin Gastroenterol Hepatol. 2023;21:81-9.e4.

31. Jense MTF, Hodde T, Palm-Meinders IH, et al. The POSE-2 procedure for people with obesity: a safe and effective treatment option. Obes Surg. 2024;34:3686-93.

32. Gys B, Plaeke P, Lamme B, et al. Endoscopic Gastric plication for morbid obesity: a systematic review and meta-analysis of published data over time. Obes Surg. 2019;29:3021-9.

33. Khan Z, Khan MA, Hajifathalian K, et al. Efficacy of endoscopic interventions for the management of obesity: a meta-analysis to compare endoscopic sleeve gastroplasty, AspireAssist, and primary obesity surgery endolumenal. Obes Surg. 2019;29:2287-98.

34. Moreno C, Closset J, Dugardeyn S, et al. Transoral gastroplasty is safe, feasible, and induces significant weight loss in morbidly obese patients: results of the second human pilot study. Endoscopy. 2008;40:406-13.

35. Leccesi L, Panunzi S, De Gaetano A, et al. Effects of transoral gastroplasty on glucose homeostasis in obese subjects. J Clin Endocrinol Metab. 2013;98:1901-10.

36. Familiari P, Costamagna G, Bléro D, et al. Transoral gastroplasty for morbid obesity: a multicenter trial with a 1-year outcome. Gastrointest Endosc. 2011;74:1248-58.

37. Sullivan S, Edmundowicz SA, Thompson CC. Endoscopic bariatric and metabolic therapies: new and emerging technologies. Gastroenterology. 2017;152:1791-801.

38. Tawadros A, Makar M, Kahaleh M, Sarkar A. Overview of bariatric and metabolic endoscopy interventions. Ther Adv Gastrointest Endosc. 2020;13:2631774520935239.

39. Shenoy A, Schulman AR. Advances in endobariatrics: past, present, and future. Gastroenterol Rep. 2023;11:goad043.

40. Tate CM, Geliebter A. Intragastric balloon treatment for obesity: review of recent studies. Adv Ther. 2017;34:1859-75.

41. Qureshi H, Saeed N, Jovani M. Updates in endoscopic bariatric and metabolic therapies. J Clin Med. 2023;12:1126.

42. Abdulla M, Mohammed N, AlQamish J. Overview on the endoscopic treatment for obesity: a review. World J Gastroenterol. 2023;29:5526-42.

43. Navez B, Ungureanu F, Michiels M, et al. Surgical management of acute cholecystitis: results of a 2-year prospective multicenter survey in Belgium. Surg Endosc. 2012;26:2436-45.

44. Choi SJ, Choi HS. Various intragastric balloons under clinical investigation. Clin Endosc. 2018;51:407-15.

45. Sachdev P, Reece L, Thomson M, et al. Intragastric balloon as an adjunct to lifestyle programme in severely obese adolescents: impact on biomedical outcomes and skeletal health. Int J Obes. 2017;42:115-8.

46. FDA. Summary of safety and effectiveness data (SSED): ORBERATM intragastric balloon system. 2015. Available from: http://www.accessdata.fda.gov/cdrh_docs/pdf10/P100034b.pdf. [Last accessed on 20 Jun 2025].

47. ASGE Bariatric Endoscopy Task Force and ASGE Technology Committee; Abu Dayyeh BK, Kumar N, Edmundowicz SA, et al. ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies. Gastrointest Endosc. 2015;82:425-38.e5.

48. Kozłowska-Petriczko K, Pawlak KM, Wojciechowska K, et al. The efficacy comparison of endoscopic bariatric therapies: 6-month versus 12-month intragastric balloon versus endoscopic sleeve gastroplasty. Obes Surg. 2022;33:498-505.

49. Suchartlikitwong S, Laoveeravat P, Mingbunjerdsuk T, et al. Usefulness of the ReShape intragastric balloon for obesity. Proc. 2019;32:192-5.

50. Abu Dayyeh BK, Maselli DB, Rapaka B, et al. Adjustable intragastric balloon for treatment of obesity: a multicentre, open-label, randomised clinical trial. Lancet. 2021;398:1965-73.

51. Sullivan S, Swain J, Woodman G, et al. Randomized sham-controlled trial of the 6-month swallowable gas-filled intragastric balloon system for weight loss. Surg Obes Relat Dis. 2018;14:1876-89.

52. Ienca R, Al Jarallah M, Caballero A, et al. The procedureless elipse gastric balloon program: multicenter experience in 1770 consecutive patients. Obes Surg. 2020;30:3354-62.

53. Kotinda APST, de Moura DTH, Ribeiro IB, et al. Efficacy of intragastric balloons for weight loss in overweight and obese adults: a systematic review and meta-analysis of randomized controlled trials. Obes Surg. 2020;30:2743-53.

54. Popov VB, Ou A, Schulman AR, Thompson CC. The impact of intragastric balloons on obesity-related co-morbidities: a systematic review and meta-analysis. Am J Gastroenterol. 2017;112:429-39.

55. Shah R, Davitkov P, Abu Dayyeh BK, Saumoy M, Murad MH. AGA technical review on intragastric balloons in the management of obesity. Gastroenterology. 2021;160:1811-30.

56. FDA. FDA In Brief: postmarket update on liquid-filled intragastric balloons. 2020. Available from: https://www.fda.gov/news-events/fda-brief/fda-brief-postmarket-update-liquid-filled-intragastric-balloons. [Last accessed on 20 Jun 2025].

57. FDA. Summary of safety and effectiveness data (SSED). TransPyloric Shuttle/TransPyloric Shuttle delivery device. 2019. Available from: http://www.accessdata.fda.gov/cdrh_docs/pdf10/P100034b.pdf. [Last accessed on 20 Jun 2025].

58. Rothstein RI, Kopjar B, Woodman GE, et al. Randomized double-blind sham-controlled trial of a novel silicone-filled endoscopically placed device for weight loss. Tech Innov Gastrointest Endosc. 2024;26:21-9.

59. Orlandini B, Gallo C, Boškoski I, Bove V, Costamagna G. Procedures and devices for bariatric and metabolic endoscopy. Ther Adv Gastrointest Endosc. 2020;13:2631774520925647.

60. Sauer N, Rösch T, Pezold J, et al. A new endoscopically implantable device (satisphere) for treatment of obesity - efficacy, safety, and metabolic effects on glucose, insulin, and GLP-1 Levels. Obes Surg. 2013;23:1727-33.

61. Günthert SJ, Aksan A, Schröder O, et al. Glycemic control and BMI changes after endoscopic implantation of a duodenojejunal bypass liner compared with laparoscopic Roux-en-Y gastric bypass surgery: a propensity score matching analysis. Surg Endosc. 2022;36:5979-85.

62. Igi WF, de Oliveira VL, Matar A, de Moura DTH. Role of endoscopic duodenojejunal bypass liner in obesity management and glycemic control. Clin Endosc. 2024;57:309-16.

63. Yvamoto EY, de Moura DTH, Proença IM, et al. The effectiveness and safety of the duodenal-jejunal bypass liner (DJBL) for the management of obesity and glycaemic control: a systematic review and meta-analysis of randomized controlled trials. Obes Surg. 2023;33:585-99.

64. Sandler BJ, Rumbaut R, Swain CP, et al. One-year human experience with a novel endoluminal, endoscopic gastric bypass sleeve for morbid obesity. Surg Endosc. 2015;29:3298-303.

65. Machytka E, Bužga M, Zonca P, et al. Partial jejunal diversion using an incisionless magnetic anastomosis system: 1-year interim results in patients with obesity and diabetes. Gastrointest Endosc. 2017;86:904-12.

66. Gagner M, Almutlaq L, Cadiere GB, et al. Side-to-side magnetic duodeno-ileostomy in adults with severe obesity with or without type 2 diabetes: early outcomes with prior or concurrent sleeve gastrectomy. Surg Obes Relat Dis. 2024;20:341-52.

67. Van Baar ACG, Holleman F, Crenier L, et al. Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes mellitus: one year results from the first international, open-label, prospective, multicentre study. Gut. 2019;69:295-303.

68. Haidry RJ, van Baar AC, Galvao Neto MP, et al. Duodenal mucosal resurfacing: proof-of-concept, procedural development, and initial implementation in the clinical setting. Gastrointest Endosc. 2019;90:673-81.e2.

69. Mingrone G, Van Baar AC, Devière J, et al. Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trial. Gut. 2021;71:254-64.

70. Aspire Bariatrics, Inc. AspireAssist instructions for use. 2015. Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf15/p150024d.pdf. [Last accessed on 20 Jun 2025].

71. Yoon JH, Lee HL. Current status of bariatric endoscopy in obesity control. Korean J Med. 2019;94:5-10.

72. Jirapinyo P, Kumar N, Saumoy M, Copland A, Sullivan S. Association for Bariatric Endoscopy systematic review and meta-analysis assessing the American Society for Gastrointestinal Endoscopy Preservation and Incorporation of Valuable Endoscopic Innovations thresholds for aspiration therapy. Gastrointest Endosc. 2021;93:334-42.e1.

73. Waseem A, Wawrzynski J, Maselli DB, Kucera A, Wooley C, McGowan C. Endoscopic removal of a weight-loss device with stoma closure using a tack-and-suture device. VideoGIE. 2023;8:441-2.

74. Köseoğlu HT, Kenarli K, Akbay A, et al. Intragastric injection of botulinum toxin in the treatment of obesity: a single-center study. Ther Adv Gastrointest Endosc. 2024;17:26317745241233083.

75. Yen YA, Wang CC, Sung WW, et al. Intragastric injection of botulinum toxin A for weight loss: a systematic review and meta-analysis of randomized controlled trials. J Gastroenterol Hepatol. 2022;37:983-92.

76. ASGE/ASMBS Task Force on Endoscopic Bariatric Therapy; Ginsberg GG, Chand B, Cote GA, et al. A pathway to endoscopic bariatric therapies. Gastrointest Endosc. 2011;74:943-53.

77. Whaley CM, Briscombe B, Kerber R, O’Neill B, Kofner A. Prices paid to hospitals by private health plans: findings from round 4 of an employer-led transparency initiative. 2022. Available from: https://www.rand.org/pubs/research_reports/RRA1144-1.html. [Last accessed on 20 Jun 2025].

78. AMA Category 1 CPT code for endoscopic sleeve gastroplasty (ESG). 2024. Available from: https://www.linkedin.com/posts/boston-scientific-endoscopy_endobariatrics-cptcode-medicalbillingandcoding-activity-7253049978745487361-9s0b/?utm_source=share&utm_medium=member_desktop. [Last accessed on 20 Jun 2025].